JPRN-jRCT2061220077招募中2 期
A Phase II, open-label, uncontrolled, multicenter study to evaluate efficacy and safety of M119102 in patients with alopecia areata
Tomoyuki Nishiura0 个研究点目标入组 25 人开始时间: 2022年12月23日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 12age old 至 < 65age old（—）
- 性别
- All
入选标准
- •Patients with alopecia areata 12 to 64 years old
排除标准
- •1)Individuals with a history or merger of hepatic, renal, cardiac and other cardiovascular, gastrointestinal, hematologic, blood, endocrine, respiratory, or other diseases considered inappropriate for paticipation in the clinical study.
- •(2)Individuals who are judged to be unsuitable as subject by the principal (sub) investigator.
研究者
相似试验
进行中（未招募）
1 期
A phase II, multi-centre, open-label, uncontrolled study to evaluate the efficacy and safety of BAY 43-9006 given daily in combination with repeated 21-day cycles of dacarbazine (DTIC) chemotherapy in subjects with advanced metastatic melanoma. - N/ASubjects with advanced, metastatic, histologically confirmed melanoma, for whom treatment with dacarbazine is considered medically acceptable. Subjects should have measurable and evaluable disease (as per the RECIST criteria), and not have received prior cytotoxic chemotherapy.Classification code 10027481EUCTR2004-000725-30-GBBayer HealthCare AG
进行中（未招募）
不适用
A Phase II, Open Label, Uncontrolled, Multi-Center Study to support annual strain update and to Evaluate Safety and Immunogenicity of FLUAD Surface Antigen, Inactivated, (Adjuvanted with MF59C.1) Influenza Vaccine, Formulation 2007-2008, when Administered to Subjects aged 18-64 years affected by chronic diseases - NDThe Flu vaccine is used for active prophilaxisys for the influenza, in subjects with chronic diseases (Hypertension, cardiopatie, BOCD, asthma,renal or hepatic insufficiency, arteriosclerosis and diabetes insulindependent)MedDRA version: 9.1Level: LLTClassification code 10059429Term: Influenza immunisationEUCTR2007-000964-26-ITOVARTIS VACCINES AND DIAGNOSTICS S.R.L.
进行中（未招募）
不适用
A Phase 2, Multi-center, Uncontrolled, Open-label Trial to Evaluate Safety, tolerability, and Efficacy of Orally Administered OPC-67683 as 100 mg BID with optional titration to 200 mg BID for up to Six Months Exposure in Patients with Pulmonary Multi-drug Resistant TuberculosisEUCTR2008-005107-26-LVOtsuka Pharmaceutical Development and Commercialization, Inc.430
进行中（未招募）
不适用
A Phase 2, Multi-center, Uncontrolled, Open-label Trial to Evaluate Safety, tolerability, and Efficacy of Orally Administered OPC-67683 as 100 mg BID with optional titration to 200 mg BID for up to Six Months Exposure in Patients with Pulmonary Multi-drug Resistant TuberculosisPulmonary Multidrug-resistant Tuberculosis (MDR TB)MedDRA version: 9.1Level: LLTClassification code 10037440Term: Pulmonary tuberculosisEUCTR2008-005107-26-EEOtsuka Pharmaceutical Development and Commercialization, Inc.430
招募中
2 期
A phase 2 study of S-005151 in patients with dystrophic epidermolysis bullosa to evaluate the efficacy for intractable ulcersdystrophic epidermolysis bullosaJPRN-jRCT2031220378Juan Carlos Gomez3